Sage Therapeutics, Inc. (SAGE) Given a $82.00 Price Target by SunTrust Banks, Inc. Analysts
Sage Therapeutics, Inc. (NASDAQ:SAGE) has been assigned a $82.00 target price by investment analysts at SunTrust Banks, Inc. in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s price target would indicate a potential upside of 29.13% from the stock’s current price.
Other research analysts have also recently issued reports about the company. Royal Bank Of Canada reissued a “buy” rating and set a $117.00 price objective on shares of Sage Therapeutics in a report on Wednesday. Needham & Company LLC set a $95.00 price objective on Sage Therapeutics and gave the company a “buy” rating in a report on Friday, August 4th. HC Wainwright lifted their price objective on Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Cowen and Company reissued a “buy” rating and set a $100.00 price objective on shares of Sage Therapeutics in a report on Friday, August 4th. Finally, Stifel Nicolaus began coverage on Sage Therapeutics in a report on Wednesday, August 9th. They set a “buy” rating and a $104.00 price objective for the company. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $86.79.
Sage Therapeutics (SAGE) traded up 0.92% during midday trading on Thursday, reaching $63.50. The company’s stock had a trading volume of 348,033 shares. The stock’s market cap is $2.38 billion. The stock’s 50 day moving average price is $67.78 and its 200-day moving average price is $74.13. Sage Therapeutics has a one year low of $38.30 and a one year high of $90.80.
Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same period in the previous year, the company earned ($1.08) earnings per share. On average, analysts forecast that Sage Therapeutics will post ($7.40) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/21/sage-therapeutics-inc-sage-given-a-82-00-price-target-by-suntrust-banks-inc-analysts.html.
Institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 138 shares during the last quarter. Turner Investments LLC bought a new position in shares of Sage Therapeutics in the second quarter valued at about $159,000. Dubuque Bank & Trust Co. bought a new position in shares of Sage Therapeutics in the second quarter valued at about $167,000. Canada Pension Plan Investment Board bought a new position in shares of Sage Therapeutics in the second quarter valued at about $175,000. Finally, Teacher Retirement System of Texas bought a new position in shares of Sage Therapeutics in the second quarter valued at about $202,000.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.